Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Shawnt Issakhanian"'
Autor:
Dennis J. Slamon, Jun Zhang, Ming Lu, Ke Wei Gong, Shawnt Issakhanian, Raul Ayala, Tong Luo, Athena M. Madrid, Martina S.J. McDermott, Holly K.T. Huang, Neil A. O'Brien
Supplementary Table from Tucatinib has Selective Activity in HER2-Positive Cancers and Significant Combined Activity with Approved and Novel Breast Cancer–Targeted Therapies
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::123fdd17c5247cde91fb09a18e560b00
https://doi.org/10.1158/1535-7163.22522642
https://doi.org/10.1158/1535-7163.22522642
Autor:
Alexandra Drakaki, Dennis J. Slamon, Dimitrios Iliopoulos, Vassilis Georgoulias, Allan J. Pantuck, Shawnt Issakhanian, Tong Luo, Artin Soroosh, Christina Vorvis, Swapna Mahurkar-Joshi, Filippos Koinis, Neil O'Brien, Hsiao-Wang Chen, Marina Koutsioumpa
Supplementary Figure S1. PPP2R2A mRNA levels in the excised tumors from 5637 bearing mouse xenografts. Supplementary Figure S2. PPP2R2A mRNA and protein levels upon transient silencing.Supplementary Figure S3. PPP2R2A protein levels upon transient ov
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1ec9b28d868bcc1667181d942a073ae9
https://doi.org/10.1158/1535-7163.22505146.v1
https://doi.org/10.1158/1535-7163.22505146.v1
Autor:
Alexandra Drakaki, Dennis J. Slamon, Dimitrios Iliopoulos, Vassilis Georgoulias, Allan J. Pantuck, Shawnt Issakhanian, Tong Luo, Artin Soroosh, Christina Vorvis, Swapna Mahurkar-Joshi, Filippos Koinis, Neil O'Brien, Hsiao-Wang Chen, Marina Koutsioumpa
Bladder cancer represents a disease associated with significant morbidity and mortality. MiR-21 has been found to have oncogenic activity in multiple cancers, including bladder cancer, whereas inhibition of its expression suppresses tumor growth. Her
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9ba50fe86c1965b673e352b45bd603c3
https://doi.org/10.1158/1535-7163.c.6537967.v1
https://doi.org/10.1158/1535-7163.c.6537967.v1
Autor:
Dennis J. Slamon, Jun Zhang, Ming Lu, Ke Wei Gong, Shawnt Issakhanian, Raul Ayala, Tong Luo, Athena M. Madrid, Martina S.J. McDermott, Holly K.T. Huang, Neil A. O'Brien
Pharmacologically targeting the HER2 oncoprotein with therapeutics such as the mAb, trastuzumab, provides clinical benefit for patients with HER2-positive (HER2+) cancers. However, a significant number of patients eventually progress on these therapi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6befd586bcd3d1466546f9390efb869a
https://doi.org/10.1158/1535-7163.c.6543451
https://doi.org/10.1158/1535-7163.c.6543451
Autor:
Neil A. O'Brien, Holly K.T. Huang, Martina S.J. McDermott, Athena M. Madrid, Tong Luo, Raul Ayala, Shawnt Issakhanian, Ke Wei Gong, Ming Lu, Jun Zhang, Dennis J. Slamon
Publikováno v:
Molecular cancer therapeutics. 21(5)
Pharmacologically targeting the HER2 oncoprotein with therapeutics such as the mAb, trastuzumab, provides clinical benefit for patients with HER2-positive (HER2+) cancers. However, a significant number of patients eventually progress on these therapi
Autor:
Neil A. O'Brien, Holly K. Huang, Martina S. McDermott, Athena Madrid, Tong Luo, Raul Ayala, Shawnt Issakhanian, Ke Wei Gong, Ming Lu, Jun Zhang, Dennis J. Slamon
Publikováno v:
Cancer Research. 82:LB197-LB197
Pharmacologically targeting the HER2 oncoprotein with therapeutics such as the monoclonal antibody (mAb), trastuzumab, provides clinical benefit for patients with HER2-positive (HER2+) cancers. However, a significant number of patients eventually pro
Autor:
Dylan Conklin, Neil A. O'Brien, S Hurvitz, M McDermott, Shawnt Issakhanian, Suruchi Salgar, DJ Slamon, Tong Luo, Raul Ayala
Publikováno v:
Cancer Research. 79:P6-17
Background: Pharmacologically targeting the HER2 oncoprotein provides clinical benefit for patients with HER2-amplified cancers. However, a significant number of patients do not respond to the currently approved HER2-targeted therapies, despite carry
Autor:
Swapna Mahurkar-Joshi, Allan J. Pantuck, Tong Luo, Marina Koutsioumpa, Alexandra Drakaki, Shawnt Issakhanian, Filippos Koinis, Hsiao-Wang Chen, Vassilis Georgoulias, Dimitrios Iliopoulos, Dennis J. Slamon, Christina Vorvis, Neil A. O'Brien, Artin Soroosh
Publikováno v:
Molecular Cancer Therapeutics. 17:1430-1440
Bladder cancer represents a disease associated with significant morbidity and mortality. MiR-21 has been found to have oncogenic activity in multiple cancers, including bladder cancer, whereas inhibition of its expression suppresses tumor growth. Her
Autor:
Ronald Linnartz, Shawnt Issakhanian, Karen A. McDonald, Richard S. Finn, S Hurvitz, Emmanuelle DiTomaso, NA O'Brien, Luo Tong, Raul Ayala, DJ Slamon, S Hirawat
Publikováno v:
Cancer Research. 73:PD1-5
Background: The selective mTORC1 inhibitor everolimus (RAD001/Affinitor®) has recently been approved, in combination with exemestane, for treatment of advanced hormone receptor positive breast cancer after demonstrating significantly improved progre
Autor:
Tong Luo, E Von Euw, S Hurvitz, S Wilhelm, DJ Slamon, O Politz, Ondrej Kalous, Shawnt Issakhanian, D Conklin, BH Childs, Raul Ayala, NA O'Brien
Publikováno v:
Cancer Research. 77:P3-04
Background: Genetic and epigenetic alterations in the PI3K/mTOR and cyclin D:CDK-4/6:Rb signaling axes occur frequently in breast cancer and have been attributed to resistance to both ER- and HER2-directed therapeutics. Pharmacologically targeting CD